Sponsor study identifier
Secondary identifiers
interventional
8
1 country
5
Study Start
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 2003
Actual (reported)The primary objective was to study the clinical benefit with dalteparin sodium in thromboprophylaxis in primary care medical subjects. The secondary objective was a pharmacoeconomic evaluation of hromboprophylaxis with dalteparin sodium in primary care medical subjects.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2003
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
December 2003
Actual (reported)April 4, 2008
Actual (reported)April 9, 2008
Actual (reported)Incidence of the endpoint made up of objectively demonstrated deep vein thrombosis (DVT), pulmonary embolism (PE) diagnosed by objective tests or death at the end of the follow-up period, 1 month after the end of the bedridden period.
1 month
Incidence of symptomatic deep vein thrombosis (DVT), symptomatic pulmonary embolism (PE) and tolerability at the end of the follow-up period.
1 month
Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
Pfizer Investigational Site
León, 24005, Spain
Pfizer Investigational Site
Madrid, 28001, Spain
Pfizer Investigational Site
Madrid, Spain
Pfizer Investigational Site
Parla, Spain
Pfizer Investigational Site
Torremolinos, 29620, Spain
Pfizer CT.gov Call Center
Pfizer
8 participants (actual enrollment reported by the registry).
First Submitted
April 4, 2008
First Posted
April 9, 2008
Study Start
April 2003
Date type not reportedThis date has not been verified as actual or estimated.
D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Completion
December 2003
Actual (reported)Last Updated
September 29, 2008
Record last verified: 2008-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: